Yingxin Lv

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

发表论文 7 篇 · 总被引 175 次 · h-index 5

代表论文

• Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial (2023 · The Lancet Oncology · 被引 105)
• A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901) (2023 · EClinicalMedicine · 被引 51)
• Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial (2024 · EClinicalMedicine · 被引 9)
• Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) (2026 · Journal of Clinical Oncology · 被引 5)
• Switch-on Fluorescence Analysis of Protease Activity with the Assistance of a Nickel Ion-Nitrilotriacetic Acid-Conjugated Magnetic Nanoparticle (2023 · Molecules · 被引 5)
• Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase II trial NEOCRTEC1901. (2026 · Journal of Clinical Oncology)